Arbutus Biopharma shares are trading higher after the company announced the filing of three international lawsuits seeking to enforce patent protecting LNP technology against Pfizer, BioNTech and certain or other affiliates.benzinga_article·Jul 16 at 08:08 AMBNTX+0.54%ABUS-2.72%
Arbutus Biopharma Ends RSV Agreement With Genevant; Receives $1 Million Termination FeeTradingView·Jul 16 at 06:33 AMABUS-2.72%MRNA-2.36%
Arbutus files patent infringement suits against Pfizer, BioNTech over LNP technologyPUBT·Jul 16 at 06:32 AMABUS-2.72%MRNA-2.36%
Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj lossTradingView·May 14 at 02:54 AMMRNA-2.36%ABUS-2.72%
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | ABUS Stock NewsStockTitan·May 12 at 10:30 PMABUS-2.72%
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga_article·Apr 16 at 07:03 AMGEVO-2.68%ABUS-2.72%
